The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Regeneus (RGS) has signed an agreement with Kyocera Corporation to give it exclusive negotiation rights to Progenza for treating knee osteoarthritis
  • Progenza is the company’s leading cell therapy technology for treating osteoarthritis and other musculoskeletal disorders
  • Kyocera is a major Japanese life sciences company which makes dental and medical products such as artificial joints for the knee and hip
  • Kyocera will conduct due diligence for Progenza and then pay Regeneus 100 million Japanese yen
  • The company will have until the end of July to negotiate a commercial licence for Progenza in Japan
  • Regeneus’ shares have sky rocketed 30.2 per cent and are trading for 6.9 cents each

Regenerative medicine company Regeneus (RGS) has signed a non-binding memorandum of understanding with Kyocera Corporation.

Kyocera is a major Japanese multinational life sciences company which produces dental and medical products including artificial joints for the knee and hip.

Under the agreement, Kyocera will gain exclusive negotiation rights to Regeneus’ cell therapy technology, Progenza, for the treatment of knee osteoarthritis.

Progenza is made from expanded allogeneic mesenchymal stem cells (MSCs) from human adipose tissue (connective tissue) and contains the bioactive secretions of the cells which have shown increased therapeutic benefit.

It reduces inflammation and promotes healing and repair in the damaged or diseased tissue.

Kyocera will conduct due diligence for Progenza which is expected to take no more than 45 days after the delivery of documentation. Once due diligence is completed, Kyocera will pay Regeneus 100,000,000 JPY (approx. A$1.4 million).

It will have until the end of July to negotiate a commercial licence for Progenza in Japan.

“This Memorandum of Understanding with a company of Kyocera’s prominence is an important step in the commercialisation pathway for Progenza OA in Japan,” Regeneus CEO and Executive Director Leo Lee said.

Regeneus’ shares have sky rocketed 30.2 per cent and are trading for 6.9 cents each at 12:30 pm AEDT.

RGS by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…